In October, we reported on a growing number of IPR challenges to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213 patent”) to...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
Samsung Bioepsis
-
-
On November 6, 2017, Sandoz, Inc. filed its eighth inter partes review (“IPR”) against AbbVie Biotechnology Ltd. (“AbbVie”),...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Samsung Bioepis (“Bioepis”) has joined a growing list of challengers to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On July 24, 2017, Samsung Bioepis and Merck & Co., Inc. announced the launch of Renflexis® (infliximab-abda) in the United States. ...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On June 22, 2017, the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicine’s Agency (“EMA”)...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Earlier this month, Janssen Biotech, Inc., a subsidiary of Johnson and Johnson, (“Janssen” or “Plaintiff”) filed a Complaint in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
FDA approved Samsung Bioepis’s Renflexis® (SB2, infliximab-abda) on Friday, April 21, 2017. Renflexis® is the fifth biosimilar...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Samsung Bioepsis UK Limited (“Samsung”), Biogen Idec Limited (“Biogen”), and Fujifilm Kyowa Kirin Biologic Company Limited...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]